Patient-Derived Xenograft (PDX) Model Development

The contract involves the development of patient-derived xenograft PDX models by engrafting human tumor cells into immunodeficient mice to support preclinical evaluation of gene editing therapies targeting hematologic malignancies. This effort is designed to generate biologically relevant models that reflect the genetic and phenotypic diversity of human blood cancers, enabling rigorous testing of novel therapeutic approaches before clinical translation. The work is classified under NAICS code 541715, indicating it falls under research and development in the life sciences sector and is structured as a subcontract under the National Institutes of Health, part of the Department of Health and Human Services. The solicitation was posted on June 30, 2026, with a response deadline of July 9, 2026, at 1:00 PM, indicating a tight turnaround for potential subcontractors to submit proposals. No set-aside type or specific location details are provided, suggesting the work may be performed at the contractor’s facility or at any accredited research site capable of meeting the technical and ethical standards for PDX model generation. The focus on gene editing therapies underscores a high-priority initiative in advancing precision medicine for blood cancers, with the PDX models serving as critical tools for assessing efficacy, specificity, and safety of CRISPR or other gene modification strategies in vivo.